Earnings ·
Acumen Pharmaceuticals, Inc. reported financial results for the quarter ended June 30, 2026, on August 12, 2026
ABOSAcumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc. reported financial results for the quarter ended June 30, 2026, on August 12, 2026. The company held $110.2 million in cash, cash equivalents, and marketable securities as of June 30, 2026, which is expected to fund operations into early 2027. Research and development expenses decreased to $27.8 million from $37.1 million in the prior year period due to lower manufacturing and clinical trial costs. The company expects to report topline results for its Phase 2 ALTITUDE-AD study of sabirnetug in late 2026 and targets an IND filing for its Enhanced Brain Delivery program lead candidate by mid-2027.